Colorectal Cancer

Oncology Solutions

The global burden of colorectal cancer (CRC) is expected to increase by 60 percent to more than 2.2 million new cases and 1.1 million deaths by 2030.1 Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. While the participation rates in screening are increasing, one quarter of the adults aged 50 to 75 years have never been screened.2 The five-year survival rate for colon cancer found at the local stage is 90 percent, highlighting the benefits of early detection.3

The Patient Journey

  • Advantage CTC Pro3D EC

    Efficient reading workflow solution for colonic lesion detection.

The latest in Oncology


INSIGHTS THE PULSE
1. Global patterns and trends in colorectal cancer incidence and mortality. Melina Arnold1, Mónica S Sierra1, Mathieu Laversanne1, Isabelle oerjomataram1, Ahmedin Jemal2, Freddie Bray1. Arnold M, et al. Gut 2017;66:683–691. doi:10.1136/gutjnl-2015-310912 683
2. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening2?ds=1&s=colorectal cancer
3. https://www.gastroconsa.com/colon-cancer-statistics/

JB04823XX

WIPRO GE HEALTHCARE PVT LTD
No. 4, Kadugodi Industrial Area,
Bangalore 560067,
Karnataka, India
CIN: U33111KA1990PTC01606
1800-102-2977 / +91 80 4180 1290
India.eCommerce@ge.com
Grievance Officer: Nestor J. Rivera
Chief Privacy Counsel/Officer, GE HealthCare